Clinical Research Directory

Inclusion Criteria: 1. Adults (≥18 years old) with a histologically confirmed diagnosis of cutaneous melanoma. 2. Clinical stage I or II disease, for whom sentinel lymph node biopsy (SLNB) is being considered. 3. Patients with either: * An estimated risk of sentinel lymph node metastasis between 5 and 10 percent based on the MIA risk calculator, or * A discordant risk scenario will be defined as a case in which the individualized probability of sentinel lymph node metastasis predicted by the MIA model falls into a different risk category (\<5%, 5-10%, or \>10%) than the category suggested by clinicopathologic staging features used in NCCN guideline-based counseling. 4. Willingness and ability to comply with study procedures. 5. Ability to provide informed consent. 6. Pregnant women, and other vulnerable populations are not specifically excluded unless they meet other exclusion criteria; the study presents minimal risk. Exclusion Criteria: 1. Patients with clinical evidence of nodal or distant metastatic disease at the time of consultation. 2. Patients with prior sentinel lymph node biopsy or nodal surgery for the current melanoma diagnosis. 3. Inability to speak or read English. 4. Inability or unwillingness to provide informed consent. 5. Prisoners